Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00311402
Status:
COMPLETED
Last Update Posted:
2014-02-14
First Post:
2006-03-28
Brief Title:
JASAP Japanese Aggrenox Stroke Prevention vs Aspirin Programme
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
JASAP Japanese Aggrenox Stroke Prevention vs Aspirin Programme Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox Combination Drug Containing Sustained-release Dipyridamole 200 mgAcetylsalicylic Acid 25 mg Twice Daily vs Acetylsalicylic Acid 81 mg Once Daily
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox combination drug containing sustained-release dipyridamole 200 mgacetylsalicylic acid 25 mg twice daily vs acetylsalicylic acid 81 mg once daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None